A list of downloadable documents created during development.
Melanoma (previously untreated unresectable stage III or IV) - ipilimumab [ID74]: equality impact assessment - guidance review
Melanoma (previously untreated unresectable stage III or IV) - ipilimumab [ID74]: final appraisal determination
Melanoma (previously untreated unresectable stage III or IV) -ipilimumab: Appraisal consultation
Melanoma (previously untreated unresectable stage III or IV) - ipilimumab: Equality Impact Assessment
Melanoma (previously untreated unresectable stage III or IV) - ipilimumab: response to consultee and commentator comments on the draft scope and provisional matrix
Melanoma (previously untreated unresectable stage III or IV) - ipilimumab: final matrix
Melanoma (previously untreated unresectable stage III or IV) - ipilimumab: final scope
Melanoma (previously untreated unresectable stage III or IV) - ipilimumab in combination with dacarbazine: appendix B - final scope
Melanoma (previously untreated unresectable stage III or IV) - ipilimumab in combination with dacarbazine: appendix C - final matrix
Melanoma (previously untreated unresectable stage III or IV) - ipilimumab in combination with dacarbazine: appendix D - NICE's response to consultee and commentator comments on the draft scope
Melanoma (previously untreated unresectable stage III or IV) - ipilimumab in combination with dacarbazine: equality impact assessment
Melanoma (previously untreated unresectable stage III or IV) - ipilimumab in combination with dacarbazine: appendix A - draft scope
Melanoma (previously untreated unresectable stage III or IV) - ipilimumab in combination with dacarbazine: appendix B - provisional matrix